Antibody-drug conjugates (ADC) represent a distinct family of chemoimmunotherapy agents. ADCs are composed of monoclonal antibodies conjugated to cytotoxic payloads via specialized chemical linkers. ADCs therefore combine the immune therapy with targeted chemotherapy. Due to the distinct biomarkers associated with lymphocytes and plasma cells, ADCs have emerged as a promising treatment option for lymphoid malignancies and multiple myeloma. Several ADCs have been approved for clinical applications: brentuximab vedotin, inotuzumab ozogamicin, moxetumomab pasudotox, and polatuzumab vedotin. More novel ADCs are under clinical development. In this article, we summarized the general principles for ADC design, and updated novel ADCs under various stages of clinical trials for lymphoid malignancies and multiple myeloma.

中文翻译：

---

淋巴恶性肿瘤和多发性骨髓瘤临床试验中的抗体-药物偶联物。

抗体药物偶联物 (ADC) 代表了一个独特的化学免疫治疗药物家族。ADC 由通过专门的化学接头与细胞毒性有效负载缀合的单克隆抗体组成。因此，ADC 将免疫疗法与靶向化疗结合起来。由于与淋巴细胞和浆细胞相关的独特生物标志物，ADC 已成为淋巴恶性肿瘤和多发性骨髓瘤的有前途的治疗选择。几种 ADC 已被批准用于临床应用：brentuximab vedotin、inotuzumab ozogamicin、moxetumomab pasudotox 和 polatuzumab vedotin。更多新型 ADC 正在临床开发中。在本文中，我们总结了 ADC 设计的一般原则，并更新了淋巴恶性肿瘤和多发性骨髓瘤临床试验各个阶段的新型 ADC。